Brian Helfand, MD, PhD

home / authors / brian-helfand-md-phd

Articles

Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.

Between the Lines Podcast: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer

Matthew Fowler;Brian Helfand, MD, PhD;Steven Finkelstein, MD, FACRO, Florida Cancer Affiliates

October 19th 2021

Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.

Follow-Up After Negative Bone/CT in Prostate Cancer With Molecular Recurrence 

Raoul S. Concepcion, MD, FACS;Brian Helfand, MD, PhD;Munir Ghesani, MD;Judd W. Moul, MD

May 6th 2021

Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence. 

Molecular Recurrence in Oligometastatic Prostate Cancer

Raoul S. Concepcion, MD, FACS;Brian Helfand, MD, PhD;Munir Ghesani, MD;Judd W. Moul, MD

May 6th 2021

An expert panel discusses the challenges of detecting and managing biochemical recurrence in the context of oligometastatic prostate cancer. 

Sensitivity of Imaging Modalities to Biochemical Recurrence in Prostate Cancer 

Raoul S. Concepcion, MD, FACS;Brian Helfand, MD, PhD;Munir Ghesani, MD;Judd W. Moul, MD

May 6th 2021

Dr Munir Ghesani reviews and comments on data regarding the sensitivity of imaging modalities in detecting biochemical recurrence in prostate cancer. 

Case 2: 64-Year-Old Man With Multifocal Prostate Cancer Post-IMRT

Raoul S. Concepcion, MD, FACS;Brian Helfand, MD, PhD;Munir Ghesani, MD;Judd W. Moul, MD

April 29th 2021

Dr Raoul Concepcion leads a panel discussion on a case of a 64-year-old man with multifocal prostate cancer treated with IMRT who refused ADT. 

Considerations for Tracer Selection to Assess Biochemical Recurrence in Prostate Cancer 

Raoul S. Concepcion, MD, FACS;Brian Helfand, MD, PhD;Munir Ghesani, MD;Judd W. Moul, MD

April 29th 2021

Munir Ghesani, MD, an expert in nuclear medicine, describes the factors that differentiate available tracers and provides guidance on tracer selection. 

Imaging Modalities for Evaluating Biochemical Recurrence in Prostate Cancer 

Raoul S. Concepcion, MD, FACS;Brian Helfand, MD, PhD;Munir Ghesani, MD;Judd W. Moul, MD

April 22nd 2021

An expert panel reacts to polling data on choice of imaging modalities for patients with prostate patients after definitive therapy and share their insights about best practices.  

Case 1: 58-Year-Old Man 6 Months Post-Radical Prostatectomy 

Raoul S. Concepcion, MD, FACS;Brian Helfand, MD, PhD;Munir Ghesani, MD;Judd W. Moul, MD

April 22nd 2021

Raoul Concepcion, MD, presents the case of a 58-year-old man who had a radical prostatectomy 6 months prior and discusses how aspects of the case influence treatment selection. 

Considerations for Initiating ADT After Biochemical Recurrence in Prostate Cancer 

Raoul S. Concepcion, MD, FACS;Brian Helfand, MD, PhD;Munir Ghesani, MD;Judd W. Moul, MD

April 15th 2021

Experts in prostate cancer discuss considerations for initiating ADT therapy after definitive treatment in patients with prostate cancer in the context of biochemical recurrence. 

Defining PSA Nadir After Definitive Therapy in Prostate Cancer 

Raoul S. Concepcion, MD, FACS;Brian Helfand, MD, PhD;Munir Ghesani, MD;Judd W. Moul, MD, FACS

April 15th 2021

Brian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer. 